Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunization
Scientists at Gorlaeus Laboratories report research in immunization
July 9th, 2008
New research, 'Vaccination against CD99 inhibits atherogenesis in low-density lipoprotein receptor-deficient mice,' is the subject of a report. "Murine CD99 was recently found to be expressed on leukocytes and endothelial cells, where it is concentrated at inter-endothelial contacts. Blockade of CD99 by specific antibodies inhibits leukocyte extravasation to inflamed sites in vivo," investigators in Netherlands report. "The aim of the present study is to show the role of CD99 in atherosclerosis using a CD99 vaccination protocol to block the function of CD99 during atherosclerosis. We constructed a DNA vaccine against CD99 by cloning the extracellular domain of murine...
Source: Vaccine Weekly (2008-07-09)
|
